Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of research firms recently commented on RANI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Rani Therapeutics in a research note on Friday, January 9th.

Rani Therapeutics Stock Performance

Shares of NASDAQ RANI opened at $1.29 on Friday. Rani Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $3.87. The company has a market cap of $156.75 million, a PE ratio of -1.63 and a beta of 0.41. The business has a 50-day simple moving average of $1.35 and a two-hundred day simple moving average of $1.18.

Institutional Trading of Rani Therapeutics

Large investors have recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC raised its stake in shares of Rani Therapeutics by 12.7% in the fourth quarter. Kestra Private Wealth Services LLC now owns 254,812 shares of the company’s stock worth $344,000 after purchasing an additional 28,670 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Rani Therapeutics in the 4th quarter worth approximately $40,000. CWA Asset Management Group LLC increased its holdings in Rani Therapeutics by 80.0% in the 3rd quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after buying an additional 66,667 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Rani Therapeutics during the 4th quarter worth approximately $93,000. Finally, Farallon Capital Management LLC acquired a new stake in Rani Therapeutics during the 4th quarter valued at approximately $105,000. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.